On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
ThursdayMay 23, 2013 9:50 am

ECOtality, Inc. (ECTY) Unveils Blink HQ Line of EV Chargers

ECOtality yesterday announced that it was unveiling its new line of home electric vehicle (EV) chargers. The Blink HQ family of Level 2 EV chargers will each come bundled with a free membership to the Blink Network as well as a $100 charging credit. ECOtality is focused on developing and marketing ecologically-friendly energy products, such as its flagship line of Blink products, which allow for electric vehicle charging. The company also develops Minit Charger products that allow for EV charging in industrial environments. ECOtality also maintains two wholly owned and independently operated subsidiaries: Innergy Power and Fuel Cell Store. The…

Continue Reading

ThursdayMay 09, 2013 1:38 pm

BG Medicine, Inc. (BGMD) Names Dr. Paul Sohmer as New CEO

BG Medicine is a diagnostics company focused on the development and commercialization of novel cardiovascular tests. The company has two products: the Galectin-3 test for use in patients with chronic heart failure and the CardioSCORE test for the risk prediction of major cardiovascular events. The company announced today that it has appointed Paul Sohmer, M.D., as its president and chief executive officer and a member of its Board of Directors. He replaces Eric Bouvier as CEO. Dr. Sohmer brings more than 25 years of experience leading the growth of commercial-stage companies focused on diagnostics, laboratory services, and medical devices. Dr.…

Continue Reading

WednesdayApr 10, 2013 9:38 am

ZIOPHARM Oncology, Inc. (ZIOP) Announces Presentation of Preclinical Data Supporting DNA-Based IL-12 Therapy for Breast Cancer

Yesterday, cancer therapy-focused biopharmaceutical company ZIOPHARM Oncology announced the presentation of results from a study in a breast cancer murine model. The study demonstrated the anti-tumor effects and tolerability of Ad-RTS-mIL-12, which is a viral vector DNA-based therapeutic for the controlled, local expression of IL-12 – an important protein for enhancing antitumor immunity. The data was presented at the American Association for Cancer Research 2013 Annual Meeting, taking place in Washington, D.C., April 6-10. The study was jointly conducted by Intrexon Corporation and ZIOPHARM, which is Intrexon’s exclusive channel partner for the development of in vivo oncology therapeutics. During the…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered